Pulmonary Fibrosis

Latest News

Doctor looking at lung imaging | Image credit: shidlovski – stock.adobe.com
Deep Learning Biomarkers Help Uncover ENV-101 Treatment Effects in IPF

June 26th 2025

At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those receiving placebo.

Patients in the 60 mg arm had a mean increase in FVC of 98.4 ml while the placebo group had a drop in FVC of 20.3 ml. | Image credit: Angelov - stock.adobe.com
AI-Derived Therapy for IPF Shows Potential in Phase 2a Trial

June 14th 2025

Providers reported issues with accessing diagnostic tests, such as laboratory and lung function tests, and limited availability of pulmonary rehabilitation and home oxygen for rural patients. | Image credit: BJP7images - stock.adobe.com
Patients With ILD in Rural Areas Face Barriers to Care

June 7th 2025

Patients often managed their treatment on their own, with more than half of patients adjusting the dose of their antifibrotic, either by lowering their dose, skipping doses, or interrupting treatment. | Image Credit: underverse - stock.adobe.com
Patients With IPF Face QOL Challenges With Antifibrotic Treatment

May 27th 2025

Data from this new study show that cutoffs as low as 2% were associated with poor outcomes in IPF, even when accounting for other known prognostic factors. | Image Credit: Crystal light - stock.adobe.com
Real-World Findings Suggest New Look at Thresholds for IPF Progression

May 22nd 2025

Advancing IPF Care: New Evidence and Economic Considerations in Treatment Decision-Making

Learn about the clinical and economic burden of idiopathic and progressive pulmonary fibrosis; the need for earlier diagnosis and improved care coordination; and emerging therapies that may close treatment gaps.

AJMC Peer Exchange logo displayed on a blue geometric background with layered diamond shapes.

More News

Justin Oldham, MD, MS, an expert on IPF
August 1st 2024

Therapeutic Response and Disease Progression

Justin Oldham, MD, MS
An expert on idiopathic pulmonary fibrosis describes the therapeutic response of standard-of-care treatments and how multidisciplinary care can be optimized when treating patients.
Justin Oldham, MD, MS, an expert on IPF
August 1st 2024

Current Standard of Care in IPF

Justin Oldham, MD, MS
Justin Oldham, MD, MS, discusses the current standard of car in treating idiopathic pulmonary fibrosis and the role of non-pharmacologic therapies.
Justin Oldham, MD, MS, an expert on IPF
August 1st 2024

Advice for Clinicians Treating IPF

Steven D. Nathan, MD
Dr Nathan provides his final thoughts regarding IPF management.
Justin Oldham, MD, MS, an expert on IPF
August 1st 2024

Future Possibilities in IPF Treatment

Steven D. Nathan, MD
Dr Nathan discusses the trajectory of IPF management.
Justin Oldham, MD, MS, an expert on IPF
August 1st 2024

Importance of Patient-Reported Outcomes

Steven D. Nathan, MD
Steven Nathan, MD, continues a discussion surrounding the patient journey in through IPF treatment.
Justin Oldham, MD, MS, an expert on IPF
August 1st 2024

IPF and PDE4B Inhibitors

Steven D. Nathan, MD
Dr Nathan highlights the role of PDE4B inhibitors in IPF management.
Justin Oldham, MD, MS, an expert on IPF
August 1st 2024

Emerging Agents in IPF Treatment

Steven D. Nathan, MD
Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis.
Patient pouring pills into hand | Image credit: doucefleur – stock.adobe.com
July 24th 2024

Patient Response to Pirfenidone, Nintedanib for IPF Differs in Real World vs Trials

Hayden E. Klein
While both drugs slowed down lung function decline in idiopathic pulmonary fibrosis (IPF), they were also linked to more deaths and increased incidence of acute exacerbation of IPF in real-world settings.
Doctor holding piggy bank | Image credit: Andy Dean – stock.adobe.com
July 24th 2024

Oxygen Therapy for Fibrosing ILD Tied to Higher Costs, Mortality

Hayden E. Klein
Patients with fibrosing interstitial lung disease (ILD) who began supplemental oxygen therapy had triple the per patient per month ILD-related health care costs compared with those who did not.
Doctor using stethoscope to listen to lungs | Image credit: peopleimages.com – stock.adobe.com
July 13th 2024

How Diabetes Impacts Pulmonary Vascular Dysfunction and Fibrosis

Hayden E. Klein
Type 2 diabetes and prediabetes can both significantly impact pulmonary health, highlighting the need for early detection and intervention.
Stethoscope on stack of books | Image credit: ronstik – stock.adobe.com
July 10th 2024

Pulmonary Fibrosis, Macrophage Research Jumped Since 2020

Hayden E. Klein
The annual number of publications on macrophages and pulmonary fibrosis jumped during 2017 and 2020, with signs pointing to more focus on research in these fields.
IPF | Image credit: Sviatlana – stock.adobe.com
July 3rd 2024

Study Identifies P2RX7 as Key Player in IPF Pathogenesis, Therapy

Hayden E. Klein
Research highlighted the pivotal role of P2RX7 in driving inflammatory and fibrotic processes in idiopathic pulmonary fibrosis (IPF).
Person taking pills | Image credit: fizkes – stock.adobe.com
June 28th 2024

Many Patients With IPF Continue on Antifibrotics for 3 Years

Hayden E. Klein
However, registry data also showed no significant difference in transplant-free survival and time to pulmonary function decline between patients receiving antifibrotics vs placebo.
Clinical research graphic shaped like lightbulb | image credit: ArtemisDiana – stock.adobe.com
June 25th 2024

Report Highlights Advancements in 2024 Idiopathic Pulmonary Fibrosis Pipeline

Hayden E. Klein
More than 100 therapies for idiopathic pulmonary fibrosis are being developed across the globe.
Woman running hand through hair | Image credit: Alessandro Grandini – stock.adobe.com
June 12th 2024

Hair Metabolome May Help Diagnose Pulmonary Fibrosis

Hayden E. Klein
The proof-of-concept study also identified key metabolites that correlated with pulmonary fibrosis diagnosis and disease progression.
Image of lungs and a doctor with a vial labelled COVID-19 | Image credit: Image credit: Mongkolchon - stock.adobe.com
June 11th 2024

IPF and COPD Associated With Poor COVID-19 Outcomes

Kevin Kunzmann
Idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and other interstitial lung diseases are more significantly associated with poor 30-day outcomes from COVID-19 compared with asthma.
Lungs
August 6th 2020

Patients With IPF Are at Increased Risk for Multiple Cancers

Skylar Jeremias
Researchers found that patients with idiopathic pulmonary fibrosis (IPF) are at increased risk of developing several forms of cancer compared with the general population.
Multidisciplinary Collaborative Care Reduces Costs, Improves End-of-Life Care for Patients With IPF
July 25th 2020

Multidisciplinary Collaborative Care Reduces Costs, Improves End-of-Life Care for Patients With IPF

Jaime Rosenberg
In the last 3 months of life, health care costs were significantly lower for patients receiving multidisciplinary collaborative care than for patients receiving specialized care or nonspecialized care. The differences in costs were primarily driven by differences in hospitalizations and emergency department visits.
Patient-Reported Outcomes Linked to Mortality in Idiopathic Pulmonary Fibrosis
June 5th 2020

Patient-Reported Outcomes Linked to Mortality in Idiopathic Pulmonary Fibrosis

Rachel Lutz
The study sought to determine whether patient-reported outcomes are linked with death beyond clinical risk factors in patients with idiopathic pulmonary fibrosis (IPF).
Nintedanib Exhibits Superior Cost-effectiveness to Pirfenidone for Treatment of IPF, Study Finds
January 25th 2020

Nintedanib Exhibits Superior Cost-effectiveness to Pirfenidone for Treatment of IPF, Study Finds

Alison Rodriguez
Researchers compared the cost-effectiveness of ninetedanib to pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) and found nintedanib to be more cost-saving than pirfenidone, according to study findings.
Emerging Therapeutic Innovations for Treatment of Idiopathic Pulmonary Fibrosis
January 17th 2020

Emerging Therapeutic Innovations for Treatment of Idiopathic Pulmonary Fibrosis

Matthew Gavidia
Researchers highlight new therapeutic attempts and potential future approaches to treating idiopathic pulmonary fibrosis, a chronic, fibrosing idiopathic interstitial lung disease.
Concurrent Decline in FVC, Walking Test More Likely Associated With Disease Progression in IPF
May 18th 2019

Concurrent Decline in FVC, Walking Test More Likely Associated With Disease Progression in IPF

Samantha DiGrande
In a study to be presented at the American Thoracic Society (ATS) Annual Meeting, held in Dallas, Texas on May 17-22, 2019, researchers investigated visit-to-visit variability in the forced vital capacity (FVC) of patients with idiopathic pulmonary fibrosis (IPF).
Real-World Study Finds High Adherence, Persistence With Pirfenidone Treatment in IPF
May 10th 2019

Real-World Study Finds High Adherence, Persistence With Pirfenidone Treatment in IPF

Samantha DiGrande
During the American Thoracic Society’s Annual Meeting in Dallas, Texas, taking place May 17-22, 2019, researchers will present findings from a study investigating pirfenidone (Esbriet) in the treatment of idiopathic pulmonary fibrosis (IPF) in a real-world setting.
<123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo